Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mayne Pharma (MAYNF)

Mayne Pharma (MAYNF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.39
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2549 unch
on 08/12/20
0.3240 -21.33%
on 07/24/20
+0.0049 (+1.96%)
since 06/30/20
3-Month
0.2250 +13.29%
on 06/26/20
0.3450 -26.12%
on 06/10/20
-0.0201 (-7.31%)
since 05/11/20
52-Week
0.1207 +111.18%
on 03/19/20
0.4200 -39.31%
on 10/02/19
-0.0701 (-21.57%)
since 08/12/19

Most Recent Stories

More News
Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US

, /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration...

MAYNF : 0.2549 (-1.96%)
Acne Medication Market 2020 Global Trends, Share, Growth, Analysis, Opportunities, And Forecast To 2028

This detailed market study covers acne medication market growth potentials which can assist the stakeholders to understand key trends and prospects in the acne medication market identifying the growth...

GSK : 42.16 (+2.11%)
MAYNF : 0.2549 (-1.96%)
NSRGY : 119.3100 (+1.83%)
PFE : 38.33 (+1.43%)
TEVA : 11.64 (-0.68%)
VRX.TO : 30.80 (-3.33%)
Mayne Pharma launches BAC 300 capsules in the United States

, /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine (BAC) capsule 50mg/300mg/40mg in . Mayne Pharma received approval from...

MAYNF : 0.2549 (-1.96%)
Mayne Pharma launches BAC 300 capsules in the United States

ADELAIDE, Australia , May 22, 2020 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine (BAC) capsule 50mg/300mg/40mg in...

MAYNF : 0.2549 (-1.96%)
Mayne Pharma Submits New Drug Application for E4/DRSP to the FDA

Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration...

MAYNF : 0.2549 (-1.96%)
Global Acne Drugs Market Expected to Deliver Dynamic Progression until 2029| Johnson & Johnson, Nestle S.A. (Galderma S.A.) and Allergan Plc

Global Acne Drugs Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property Analysis, Market Attractiveness,...

GSK : 42.16 (+2.11%)
MAYNF : 0.2549 (-1.96%)
PFE : 38.33 (+1.43%)
TEVA : 11.64 (-0.68%)
VRX.TO : 30.80 (-3.33%)
Acne Drugs Market Growth Opportunities on Sales, Technological Advancements and Revenue Overview 2019-2028

AGN : 193.02 (+0.02%)
GSK : 42.16 (+2.11%)
MAYNF : 0.2549 (-1.96%)
TEVA : 11.64 (-0.68%)
VRX.TO : 30.80 (-3.33%)
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

ADELAIDE, Australia, Oct. 2, 2019

MAYNF : 0.2549 (-1.96%)
Mayne Pharma launches Lexette (TM) (halobetasol propionate) foam 0.05% in the United States

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of LEXETTE(TM) (halobetasol propionate) Foam 0.05% in the United States.

MAYNF : 0.2549 (-1.96%)
TOLSURA (TM) (SUBA®-itraconazole) Antifungal Capsule Now Available in the United States

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of TOLSURA(TM) (SUBA®-itraconazole) 65mg capsule in the United States. TOLSURA is a new formulation of itraconazole indicated for...

MAYNF : 0.2549 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MAYNF with:

Key Turning Points

2nd Resistance Point 0.2549
1st Resistance Point 0.2549
Last Price 0.2549
1st Support Level 0.2549
2nd Support Level 0.2549

See More

52-Week High 0.4200
Fibonacci 61.8% 0.3057
Fibonacci 50% 0.2703
Last Price 0.2549
Fibonacci 38.2% 0.2350
52-Week Low 0.1207

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar